Phase 2 / Phase 3 trials
Phase 2 / Phase 3 trials
Explore registered studies and their research locations.1,277 results · Page 1 of 52
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Sex Chromosome Disorders, X-linked disease, autism, autism spectrum disorder, chromosomal disorder, fragile X syndrome, hereditary disease, inherited neurodegenerative disorder, intellectual disability, nervous system disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07439510 | |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07100080 | |
| Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Infant, Premature, Diseases, Lung Injury, Ventilator-Induced Lung Injury, bronchopulmonary dysplasia, lung disorder, respiratory system disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT06897839 | |
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Disorders of Excessive Somnolence, Dyssomnias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, idiopathic hypersomnia, narcolepsy, narcolepsy without cataplexy, narcolepsy-cataplexy syndrome, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT06767683 | |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT06616584 | |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7 | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05987241 | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, cystic hygroma, lymphangioma, lymphatic system disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05948943 | |
| HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, erythropoietic protoporphyria, hepatic porphyria, hereditary disease, hereditary skin disorder, liver disorder, metabolic disease, porphyria, skin disorder | Enrolling by invitation | Phase 2 / Phase 3 | 2026-10-09 | NCT05883748 | |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, subacute cutaneous lupus erythematosus, systemic lupus erythematosus | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05531565 | |
| Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer | MSS-type Low Rectal Cancer，Neoadjuvant Chemoradiotherapy, QL1706 | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07866313 | |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07865910 | |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07634471 | |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07592273 | |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07570173 | |
| A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients | High-Risk Neuroblastoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07549321 | |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07392892 | |
| Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07226999 | |
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | SCLC | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07145333 | |
| Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD | Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, cognitive disorder, psychiatric disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT06495476 | |
| Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia | Disease Attributes, Healthcare-Associated Pneumonia, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pneumonia, Ventilator-Associated, iatrogenic disease, lung disorder, nosocomial infection, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT06488794 | |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | esophageal adenocarcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT06203600 | |
| Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05987956 | |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05139017 | |
| Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05062837 | |
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05058651 |